



Monitor

A non-invasive test to de-intensify the surveillance of bladder cancer

Cxbladder Monitor is a non-invasive genomic urine test that can reduce the burden of repeated cystoscopy in those being monitored for recurrent non-muscle invasive bladder cancer.



With the option of in-home sampling to maximize patient comfort and convenience.


Non-compliance: The challenge for clinicians

Recent American Urological Association (AUA) registry data¹ suggests that the average length of follow-up monitoring among NMIBC patients is 1.8 years. This contrasts to the 5 year AUA surveillance guideline for low risk patients and the ongoing monitoring recommendation for those at higher risk.



2023 Survey: Patients Show Strong Interest in Non-Invasive Test Options

In December 2023, 1,507 patients being monitored for recurrent non-muscle invasive bladder cancer (NMIBC) were questioned using the Bladder Cancer Advocacy Network's (BCAN's) Patient Survey Network².



Patients were receptive to urine-based testing

80% of patients said having a urine-based surveillance test alternative was moderately to extremely important.

Surveyed patients were then presented with introductory information on Cxbladder Monitor and asked if they would be willing to use the test to reduce the frequency of surveillance cystoscopy.

90%
were interested and wanted to learn more

Cxbladder Monitor combines both genotypic factors and patient clinical information to reliably rule out those patients with a low probability of urothelial cancer, reducing the frequency of cystoscopy required.

- Spare patients the discomfort, anxiety, risk, and inconvenience of an invasive procedure.
- Improve compliance with scheduled surveillance checks.
- Focus your in-clinic resources on those that need care.
- Empower your team and improve time utilization to maximize overall efficiency.

1. AUA AQUA Registry Data, 2023.


2. BCAN Patient Network Survey – Non-Invasive Testing for Surveillance of NMIBC, 2023.

A non-invasive test to de-intensify the surveillance of bladder cancer

93%
SENSITIVITY97%
NPV

High Sensitivity and high Negative Predictive Value (NPV) provides greater confidence in the rule out of recurrent urothelial carcinoma (UC).

Sensitivity of Cxbladder Monitor in Clinical Study³



High NPV and high sensitivity combined are required to get a clinically meaningful resolution.

3. Lotan et al: Clinical comparison of non-invasive urine tests for ruling out recurrent urothelial carcinoma. Urologic Oncology (2017).

A non-invasive test to de-intensify the surveillance protocols of NMIBC

- Alternate with cystoscopy to de-intensify surveillance post the most recent diagnosis of UC (>9 months).
- Replace cystoscopy in patients with no recurrence long term after shared decision making with patient (low risk: 3+ years, high: 5+ years).

Cxbladder Monitor, with the option of in-home sampling, is a non-invasive surveillance alternative that can reduce the burden of repeated cystoscopy in NMIBC patients with a low risk of recurrent UC, improving comfort and compliance.

Learn more

Visit us online at www.cxbladder.com
Follow our updates at www.twitter.com/cxbladder

Contact us

Email: info@cxbladder.com

02-MKT-118-US-Rev-A

